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Abstract The dystrophin-glycoprotein complex is a multi-
subunit protein complex that spans the muscle plasma membrane
(sarcolemma) and forms a link between the intracellular
cytoskeleton and the extracellular matrix. Caveolin-3, the muscle
specific form of caveolin, is also a major structural and
regulatory integral membrane protein found at the sarcolemma.
Oligomers of caveolin-3 form the structural framework for small
membrane pockets known as caveolae. We directly examined
whether caveolin-3 is an integral component of the dystrophin-
glycoprotein complex by examining four common biochemical
and cellular properties of proteins integrally bound to the
dystrophin-glycoprotein complex. We found that caveolin-3 de-
enriches with partial purification of the dystrophin-glycoprotein
complex although a small amount of caveolin-3 is present.
Sucrose gradient fractionation and laminin affinity chromatog-
raphy completely separate this residual caveolin-3 from the core
components of the dystrophin-glycoprotein complex. We also
show that caveolin-3 expression at the sarcolemma is not reduced
in patients with primary mutations in either dystrophin or the
sarcoglycans. This data demonstrates that localization of
caveolin-3 to the sarcolemma occurs independently of the
dystrophin-glycoprotein complex and that caveolin-3 is not an
integral component of the dystrophin-glycoprotein complex.
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1. Introduction
The dystrophin-glycoprotein complex (DGC) consists of
both peripheral and integral membrane proteins and spans
the skeletal muscle plasma membrane known as the sarcolem-
ma. Puri¢cation of the DGC from rabbit skeletal muscle has
led to the identi¢cation of many of its constituent proteins
and has provided insights into the function of this large oli-
gomeric complex [1^4]. In addition to dystrophin, the DGC is
composed of K/L-dystroglycan, the sarcoglycans (K, L, Q, and
N subunits), the syntrophins, and a 25-kDa hydrophobic pro-
tein known as sarcospan [1^3,5]. Disruption of the DGC even-
tually progresses to muscle cell necrosis, as evidenced by the
dystrophic muscle phenotypes that result from defects in sev-
eral of the DGC components (for reviews, see [6,7]).
The DGC is known to be essential for normal muscle phys-
iology, although its precise role remains to be determined.
One function ascribed to the dystrophin-glycoprotein complex
is to confer stability to the sarcolemma, protecting it from
damage that might otherwise result from shear forces gener-
ated during repeated contraction of muscle ¢bers [8,9]. While
this is indeed likely to be true, the organization of the DGC
into distinct subcomplexes [10] suggests that the complex may
contribute in multiple ways to muscle cell function. One pos-
sibility is that the link between the extracellular matrix and
the cell interior provides a framework for signal transduction
across the muscle cell membrane. K-Dystroglycan is structur-
ally positioned for such a role as it binds laminin-2 in the
extracellular matrix and is attached to the membrane by its
association with L-dystroglycan and the sarcoglycans [11^13].
Caveolin-3, a 21^24-kDa integral membrane protein, is also
an important structural and regulatory component of the sar-
colemma [14^18]. Oligomers of caveolin form the sca¡old of
caveolae pockets, which are non-clathrin coated membrane
invaginations (for reviews, see [19,20]). Caveolae are thought
to concentrate signaling events located at or near the surface
of the plasma membrane of most cell types, including skeletal
muscle [21^25]. Immunoprecipitation and subcellular fraction-
ation studies from di¡erentiated C2C12 mouse myotubes
suggest that dystrophin may be associated with caveolin-3
[26]. These experiments, however, do not probe for high af-
¢nity interactions and are not criteria for examining integral
components of the dystrophin-glycoprotein complex. Thus,
we undertook to determine whether caveolin-3 is an integral
component of the dystrophin-glycoprotein complex.
2. Materials and methods
2.1. Protein preparations
The DGC was extracted with 1% digitonin from rabbit skeletal
muscle KCl-washed microsomes [27] and then puri¢ed by sWGA
a⁄nity chromatography followed by ion exchange on a DEAE col-
umn, as described previously [1,2,28].
2.2. DGC sucrose gradients
DGC fractions from the DEAE column were pooled and concen-
trated to 800 Wl. The samples were applied to a 5^30% sucrose gra-
dient and centrifuged with a Beckman VTi65.1 vertical rotor at
200 000Ug for 90 min at 4‡C [2,28]. The gradients were fractionated
into 800-Wl fractions, and 80 Wl of each fraction was resolved on 3^
15% SDS-polyacrylamide gradient gels and transferred to nitrocellu-
lose [29].
2.3. Immunoblot analysis
Immunoblot staining was performed as previously described [27].
Proteins separated by SDS-PAGE were transferred to nitrocellulose
membranes (Millipore) by the method of Towbin et al. [29]. Nitro-
cellulose transfers were blocked in TBS/blotto (20 mM Tris, 100 mM
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NaCl, pH 7.5, 3% non-fat dry milk) and subsequently incubated for
1 h with primary antibodies to DGC (goat 20, 1:500 [30]), caveolin-3
(Transduction Labs, monoclonal IgG, 1:2000 [26]), or sarcospan (rab-
bit 217, 1:20 [5]). Antibodies to the DGC were generated by immu-
nizing a goat with the DGC puri¢ed from rabbit skeletal membranes,
as described previously. The serum contains antibodies to all of the
DGC components, except sarcospan. We generated antibodies to sar-
cospan by injecting an N-terminal KLH-coupled peptide into rabbits,
as described previously [5]. The blots were washed with TBS/blotto
and incubated for 1 h with the appropriate horseradish peroxidase
conjugated secondary antibodies. The blots were developed using ei-
ther chloronaphthol (for goat 20 and sarcospan blots) or enhanced
chemiluminescence (for caveolin-3 blots, Pierce).
2.4. Laminin a⁄nity chromatography
Mouse EHS sarcoma laminin (a kind gift from Dr. Hynda K.
Kleinman at the National Institutes of Health) was coupled to
CNBr-activated Sepharose-4B (Pharmacia), as described previously
[31]. DGC (0.4 ml) was incubated at 4‡C overnight with 0.1 ml of
laminin Sepharose in the presence of 5 mM Tris-HCl, pH 7.4, 130 mM
NaCl, 0.1% digitonin, 1 mM CaCl2. The laminin-Sepharose was
centrifuged to collect the supernatants (voids), washed extensively,
and eluted with the same volume of 10 mM EDTA bu¡er. Samples
from the DGC, void, and eluate (100 Wl each) were electrophoresed on
a 3^12% SDS-PAGE and transferred to nitrocellulose.
2.5. Immuno£uorescence
Immuno£uorescence on muscle biopsies from C57/BL wild type and
mdx mice as well as control human and several Duchenne muscular
dystrophy (DMD) patients was accomplished as described [5]. Muscle
sections were incubated with antibodies to dystrophin and caveolin-3
(Transduction Labs, 1:1000) for 1 h at room temperature. After 1 h,
the sections were washed with TBS and incubated with the appropri-
ate Cy3-conjugated secondary antibodies (1:250) for 1 h. The sections
were observed under a Bio-Rad MRC-600 laser scanning confocal
microscope and the digitized images were captured under identical
conditions.
3. Results and discussion
Integral components of the dystrophin-glycoprotein com-
plex can be de¢ned by four biochemical and cellular criteria.
First, puri¢cation of the dystrophin-glycoprotein complex
from skeletal muscle membranes enriches proteins that are
associated in a complex with dystrophin. Puri¢cation of this
complex is achieved by sWGA a⁄nity chromatography fol-
lowed by ion exchange chromatography. A second character-
istic of integral DGC proteins is their migration as a complex
during high speed centrifugation through sucrose gradients.
Only proteins that bind with high a⁄nity and speci¢city will
be retained with dystrophin during sucrose gradient fraction-
ation. Previous experiments have demonstrated that the DGC
migrates as an 18S complex in sucrose gradients [32]. Third,
the core components of the DGC can be isolated by laminin
a⁄nity chromatography. K-Dystroglycan, an extracellular
component of the DGC, is a high a⁄nity receptor for laminin
[11,12,31,33] and thus binds tightly to laminin conjugated to
Sepharose. By virtue of this interaction, all members of the
complex are retained during laminin a⁄nity chromatography.
And lastly, integral components of the DGC depend on the
integrity of the complex for proper localization to the sarco-
lemma. If dystrophin is absent, as in the case of DMD pa-
tients, the entire DGC is absent from the sarcolemma. We
used these distinguishing criteria to directly determine whether
caveolin-3 is an integral component of the DGC.
As a ¢rst test for association of caveolin-3 with the DGC,
we examined partially puri¢ed DGC for the presence of cave-
olin-3. Immunoblots of puri¢ed DGC stained with DGC
antibodies show a clear enrichment of these puri¢ed proteins
relative to the levels in rabbit skeletal muscle membranes (Fig.
1). Identical immunoblots illustrate that caveolin-3 does not
enrich in DGC prepared from rabbit membranes (Fig. 1).
Dystrophin is enriched by approximately 10-fold during puri-
¢cation of the DGC, while caveolin-3 is reduced by 3-fold. A
small amount of caveolin-3 is present in the partially puri¢ed
DGC and we performed several experiments in order to de-
termine the speci¢city of this association.
The tight association of the DGC components is illustrated
by centrifugation of the DGC through sucrose density gra-
dients. Non-speci¢cally bound proteins are e⁄ciently sepa-
rated from the core components of the DGC by this method.
Proteins from the sucrose gradient fractions were separated by
SDS-PAGE. The resultant polyacrylamide gels, immunoblot-
ted with DGC antibodies, illustrate that the DGC peaks in
fractions 8^10 (Fig. 2A). Western blotting of these same frac-
tions with caveolin-3 antibodies demonstrates that caveolin-3
begins to sediment in fraction 12 and peaks in fraction 15
(Fig. 2A). Caveolin-3 migrates in the later fractions due to
its self assembly into higher order oligomers. These results
from sucrose gradient centrifugation indicate that caveolin-3
is not an integral component of the DGC and is not tightly
bound to this complex.
K-Dystroglycan has been shown to bind laminin-2 in the
extracellular matrix in a Ca2 dependent manner. We used
laminin Sepharose a⁄nity chromatography to test whether
caveolin-3 is speci¢cally associated with the DGC. The parti-
ally puri¢ed DGC was incubated with laminin conjugated
Sepharose. The void was collected from the laminin-Sephar-
ose by centrifugation and the Sepharose was subsequently
washed, and eluted with 10 mM EDTA. Treatment with
EDTA chelates calcium, causing release of bound K-dystro-
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Fig. 1. Caveolin-3 is not a component of the dystrophin glycopro-
tein complex (DGC) isolated from rabbit skeletal muscle. Caveolin-
3 does not enrich with the dystrophin-glycoprotein complex. Rabbit
skeletal muscle KCl-washed membranes (MIC), crude surface mem-
branes (CSM), and puri¢ed dystrophin-glycoprotein complex (DGC)
were electrophoretically separated on 3^15% SDS polyacrylamide
gels and transferred to nitrocellulose. Nitrocellulose transfers were
separately stained with antibodies against DGC (left panel) or
monoclonal antibodies against caveolin-3 (right panel). Molecular
size standards are indicated on the left of each panel (U103 Da).
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glycan from the laminin-Sepharose. The starting material
(DGC), void (void), and eluate (eluate) protein samples
were resolved by SDS-PAGE, transferred to nitrocellulose,
and immunoblotted with antibodies to K-dystroglycan, caveo-
lin-3, and sarcospan (Fig. 2B). Caveolin-3 did not adhere to
the laminin Sepharose and was found only in the ‘£ow
through’ or void of the column (Fig. 2B). Both K-dystrogly-
can and sarcospan bound tightly to the laminin column and
were exclusively present in the eluate. The DGC does not
completely elute from the laminin sepharose, which accounts
for the small di¡erences in the amount of K-dystroglycan in
DGC and eluate. Thus, caveolin-3 was completely separated
from the DGC by this method.
As another probe for the possible interaction between cave-
olin-3 and the DGC, we examined caveolin-3 expression in
muscle from DMD patients and the murine model for this
disease, the mdx mouse. We examined several DMD patients
with primary mutations in dystrophin, resulting in loss of the
entire dystrophin protein. Indirect immuno£uorescence assays
with antibodies against dystrophin’s N and C termini and the
central rod domain verify that dystrophin is completely absent
from the DMD sarcolemma (Fig. 3). Without dystrophin, the
other members of the complex are reduced, perhaps the result
of premature protein degradation, improper assembly of the
complex, or aberrant transportation to the sarcolemma. We
show that caveolin-3 is present at the sarcolemma in normal
and DMD muscle (Fig. 3). In addition, we found positive
caveolin-3 staining at the sarcolemma in muscle from several
FEBS 20208 7-5-98
Fig. 3. Sarcolemma localization of caveolin-3 is independent of the DGC. Immunohistochemical analysis of skeletal muscle from normal human
control (control), DMD (DMD), wild type mouse (wild type) and mdx mouse (mdx). Transverse cryosections were labeled by indirect immuno-
£uorescence with antibodies against dystrophin and caveolin-3. Absence of dystrophin in the DMD patient was con¢rmed with three separate
antibodies (not shown). Bar, 100 Wm.
Fig. 2. Dissociation of caveolin-3 from the DGC. A: Caveolin-3 separates from the DGC during sucrose gradient centrifugation. DGC puri¢ed
from rabbit skeletal muscle membranes was centrifuged through sucrose gradients. DGC proteins in fractions 7^15 from the sucrose gradient
were electrophoresed on 3^15% SDS-polyacrylamide gels. Nitrocellulose transfers of identical samples were stained with DGC and caveolin-3
antibodies. B: Puri¢cation of the DGC with laminin Sepharose removes caveolin-3. Puri¢ed DGC (input) was incubated with laminin Sephar-
ose. The void (void) and eluate (eluate) protein samples were separated by SDS-PAGE and transferred to nitrocellulose. Identical blots were
stained with K-dystroglycan, caveolin-3, and sarcospan antibodies. Molecular size standards are indicated on each panel (U103 Da).
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limb-girdle muscular dystrophy patients with primary muta-
tions in the sarcoglycans (data not shown). We also examined
caveolin-3 expression in the mdx mouse, which has a prema-
ture stop codon in the dystrophin gene resulting in absence of
the protein. We show that caveolin-3 is present in skeletal
muscle of these mice (Fig. 3). These data provide strong evi-
dence that caveolin-3 localizes to the sarcolemma independ-
ently of dystrophin.
Taken together, our results indicate that caveolin-3 is not
an integral part of the dystrophin-glycoprotein complex,
although small quantities of caveolin-3 can be detected in
partially puri¢ed DGC preparations. Sucrose gradient frac-
tionation and laminin a⁄nity puri¢cation separate the integral
components of the DGC from caveolin-3, demonstrating that
this residual caveolin-3 is not tightly bound to the DGC. Our
data do not rule out the possibility that caveolin-3 might
interact with the DGC or that the DGC may be found in
caveolae. Several membrane associated proteins (i.e. actin,
nNOS, and laminin) interact with the DGC at the sarcolem-
ma, but are not integral components of this complex. We
suspect that the DGC is assembled as a complex in the endo-
plasmic reticulum prior to translocation to the sarcolemma.
This may account for the absence of the complex when one of
the components is missing, as in the case of DMD. It is also
feasible to speculate that caveolin-3 interacts transiently with
the DGC. Such interactions could play a regulatory function
and would be consistent with the suggestion that defective
caveolin-3 might be involved in the pathophysiology of mus-
cular dystrophy. This latter suggestion is based on observed
abnormalities in caveolae size and distribution in patients with
Duchenne muscular dystrophy [34^37]. There are many exam-
ples of muscle diseases which are caused by primary defects in
proteins that are not integral components of the DGC (i.e.
emerin, calpain) and our data do not exclude the possibility
that defects in caveolin-3 may give rise to a muscular dys-
trophy phenotype.
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